donepezil

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease, Dementia

Trial Timeline

Feb 1, 2008 → Apr 1, 2009

NCT ID

NCT01023425

About donepezil

donepezil is a pre-clinical stage product being developed by Eisai for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01023425. Target conditions include Alzheimer's Disease, Dementia.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02787746	Approved	Completed	Apr 1, 2016	Mar 1, 2019	Alzheimer's Disease
NCT02550665	Phase 3	Completed	Dec 1, 2014	Oct 1, 2016	Alzheimer's Disease
NCT01023425	Pre-clinical	Completed	Feb 1, 2008	Apr 1, 2009	Alzheimer's Disease
NCT00566501	Phase 3	Completed	Dec 14, 2007	Apr 1, 2010	Alzheimer's Disease
NCT01023867	Pre-clinical	Completed	Mar 1, 2007	Jun 1, 2010	Alzheimer's Disease
NCT00381381	Approved	Completed	May 31, 2006	Dec 31, 2008	Alzheimer's Disease
NCT00220896	Approved	Completed	Jan 1, 2006	Mar 1, 2009	Cognitively Normal Elderly Individuals

Competing Products

20 competing products in Alzheimer's Disease

See all competitors

Product	Company	Stage	Hype Score
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
simufilam	Cassava Sciences	Phase 2	17
Remternetug + Placebo	Eli Lilly	Phase 3	44
solanezumab	Eli Lilly	Phase 2	35
LY2886721 + Placebo	Eli Lilly	Phase 1	29
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	39
FK962	Astellas Pharma	Phase 2	27
ASP0777 + Placebo	Astellas Pharma	Phase 1	29
Elenbecestat + Placebo	Eisai	Phase 3	32
Donepezil	Eisai	Approved	43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	40
Donepezil hydrochloride	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Pre-clinical	26